[ad_1] There are lots of ways to earn passive income, but top of my list is collecting dividends from companies. And a stock market crash could be a huge opportunity. Falling share prices mean higher dividend yields and this can…
[ad_1] “ Verrica narrows Q4 loss 72% year-over-year to -$0.51 per share as revenue surges 1,383% to $5.1M, though sequential revenue drops 65% from Q3. Newsdesk · March 11, 2026 Loss narrows sharply. Verrica Pharmaceuticals (NASDAQ: VRCA) reported Q4 2025…
[ad_1] When building a longâterm portfolio of dividend shares, itâs not just about the highest yields. What really matters is consistent growth backed by solid profits, sensible payout ratios, and a manageable balance sheet. If payouts rise 30%-70% over a…
[ad_1] “ Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate, shares jump 11.8% on improving trajectory and $893M cash position. vishnu · March 11, 2026 Loss narrows modestly. Dyne Therapeutics reported a loss of $0.76 per share for…
[ad_1] When I bought my favourite FTSE 250 stock a couple of years ago, it wasnât even in the index. It is now. Infrastructure solutions specialist Costain Group (LSE: COST) stormed back into the FTSE 250 on 2 March after a 20-year absence. It marks a…
[ad_1] “ Sprinklr Inc (CXM) delivered Q4 2025 adjusted earnings of $0.10 per share, surpassing analysts’ $0.09 forecast (beat by 10.0%). Top-line revenue was $219.1… Newsdesk · March 11, 2026 Sprinklr Inc (CXM) delivered Q4 2026 adjusted earnings of $0.13…
[ad_1] Legal & General‘s (LSE:LGEN) share price has dived in mid-week trading. At 244.2p per share, the FTSE 100 stock was down 6% on Wednesday (11 March). It’s hurtled lower after releasing full-year results that missed expectations. It’s perhaps no…
[ad_1] “ Acacia Research swings to $0.03 adjusted EPS in Q4 2025, matching prior quarter and reversing year-ago loss, as revenue holds flat at $50.1M. Newsdesk · March 11, 2026 Swings to profit. Acacia Research Corp (NASDAQ: ACTG) reported Q4…
[ad_1] Earlier this month, the Aston Martin (LSE:AML) share price hit fresh 52-week lows. At just 44p, it has already ticked one of the boxes needed to be classified as a penny share. At the moment, the market cap is…
[ad_1] “ **Tenax Therapeutics Reports Q4 2025 Results** Newsdesk · March 10, 2026 Tenax Therapeutics Inc. (TENX) posted a Q4 2025 net loss of $0.38 per share. The clinical-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States. Tenax’s…